Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.10.3.1 (
tyrosinase
)
9,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Racemic RS-4-(4-hydroxyphenyl)-2-butanol (rhododendrol; trade name: Rhododenol [RD]), which is used in topical skin-lightening cosmetics, was unexpectedly reported in Japan to induce leukoderma or vitiligo called RD-induced leukoderma (RIL) after repeated application. To our knowledge, no studies have investigated chemical-induced vitiligo pathogenesis on a genome-wide scale. Here, we conducted a genome-wide association study (GWAS) for 147 cases and 112 controls. CDH13, encoding a glycosylphosphatidylinositol-anchored protein called
T-cadherin
(
T-cad
), was identified as the strongest RIL susceptibility gene. RD sensitivity was remarkably increased by
T-cad
knockdown in cultured normal human melanocytes. Furthermore, we confirmed
tyrosinase
upregulation and downregulation of the anti-apoptotic molecules (BCL-2 and BCL-XL), suggesting that
T-cad
is associated with RD via
tyrosinase
or apoptotic pathway regulation. Finally, monobenzyl ether of hydroquinone sensitivity also tended to increase with
T-cad
knockdown, suggesting that the
T-cad
could be a candidate susceptibility gene for RIL and other chemical-induced vitiligo forms. This is the first GWAS for chemical-induced vitiligo, and it could be a useful model for studying the disease's genetic aspects.
...
PMID:Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma. 3255 22